Value through Innovation

main navigation

jump to content to meta navigation
Headillu

page content

jump to main navigation to meta navigation

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
30.04.2009 Outcome of new Mirapexin®/ Sifrol® (pramipexole) study set to change treatment of depressive symptoms in Parkinson`s disease - For medical media, outside the US only
29.04.2009 New study results support once daily, prolonged release formulation of Mirapexin®/ Sifrol®(pramipexole) for the treatment of Parkinson`s disease - For medical media, outside the US only
28.04.2009 No increased risk of treatment-induced augmentation in Restless Legs Syndrome (RLS) demonstrated in long-term placebo-controlled study with Mirapexin®/ Sifrol® (pramipexole) - For medical media, outside the US only
21.04.2009 Boehringer Ingelheim maintains its growth path in 2008, again growing faster than the pharmaceutical market - major investments once again in Research and Development - good outlook for further growth in 2009
23.03.2009 The European Porcine-Circovirus-Research-Award honours scientists from Denmark, France and Netherlands
20.03.2009 Boehringer Ingelheim`s novel oral anticoagulant dabigatran etexilate is the frontrunner for stroke prevention in atrial fibrillation: final patient completes treatment in the RE-LY® study, the largest atrial fibrillation outcomes trial to date - For medical media, outside the US only
19.03.2009 Experts unite to create new online resource for Restless Legs Syndrome - For medical media, outside the US only
03.03.2009 New diagnostic tool helps health care professionals accurately diagnose Hypoactive Sexual Desire Disorder (HSDD) in women - For medical media, outside the US only
06.02.2009 Boehringer Ingelheim Foundation makes huge investment in cutting-edge research at the Johannes Gutenberg University of Mainz
30.01.2009 Duloxetine significantly reduced osteoarthritis knee pain in new study
28.01.2009 ECASS 3 study receives recognition from the European Stroke Organisation and The Lancet - For medical media, outside the US only
10.12.2008 Study showed new episodes of depression delayed in people taking Duloxetine
19.11.2008 Winners announced for 2008 Eloquium Award
17.11.2008 First pivotal trials begin for Boehringer Ingelheim’s novel triple angiokinase inhibitor Vargatef™ (BIBF 1120) - For medical media, outside the US only
11.11.2008 Longest follow-up period for any new oral anticoagulant explores Pradaxa® (dabigatran etexilate) for stroke prevention in atrial fibrillation (AF) - For medical media, outside the US only
31.10.2008 Largest study of its kind reveals low sexual desire is most common female sexual problem - For medical media, outside the US only
30.10.2008 Closing in on the cause of diabetes
24.10.2008 European CHMP adopts negative opinion on Cymbalta for the treatment of fibromyalgia - For medical media, outside the US only
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
back to top

Contact

Boehringer Ingelheim GmbH

Corporate Headquarters
Binger Str. 173
55216 Ingelheim
Germany


Phone +49 / 6132 / 77 0
Fax +49 / 6132 / 72 0

media contacts

RSS feeds allow you to receive latest news and information about Boehringer Ingelheim.

subscribe to RSS Feed